Answers are grounded in this paper and cite their sources.
A personal anecdote highlighting the long-term management of doxorubicin-induced cardiomyopathy with standard heart failure therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Paolo Raggi (2023) conducted an editorial in Dilated cardiomyopathy. Beta-blockers and angiotensin-converting enzyme inhibitors was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: